A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting now · Phase 1

Conditions studied: Relapsed and/or Refractory Multiple Myeloma

In brief

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

Key facts

Study ID

NCT06153251

Run by

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

People needed

187

Starts

2024-01-23

Expected to finish

2030-05-02

Last updated by the study team

2026-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have a diagnosis of multiple myeloma with relapsed and/or refractory disease.
• Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry.
• Participants in Part A and Part B Cohort 1 and in Part B Cohort 2 must have relapsed/refractory multiple myeloma and received previous antimyeloma therapy, including a proteasome inhibitor and an immunomodulatory agent.
• Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Participants must have adequate organ function.

You may not qualify if…

• Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma.
• Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis.
• Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis.
• Other protocol-defined inclusion/exclusion criteria apply.

Where it is running

• Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca — Salamanca, Spain (enrolling)
• City of Hope Comprehensive Cancer Center — Duarte, California, United States (enrolling)
• UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco, California, United States (enrolling)
• Stanford University Medical Center — Stanford, California, United States (enrolling)
• Colorado Blood Cancer Institute — Denver, Colorado, United States (enrolling)
• Yale Cancer Center — New Haven, Connecticut, United States (enrolling)
• Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Icahn School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
• Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
• University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)
• Tennessee Oncology — Nashville, Tennessee, United States (enrolling)
• Swedish Medical Center — Seattle, Washington, United States (enrolling)
• Hôpital Saint-Louis — Paris, France (enrolling)
• Universitaetsklinikum Koeln — Cologne, Germany (enrolling)
• Universitaetsklinikum Heidelberg — Heidelberg, Germany (enrolling)
• Universitaetsklinikum Wuerzburg — Würzburg, Germany (enrolling)
• Clinica Universidad de Navarra — Pamplona, Navarre, Spain (enrolling)
• Local Institution - 0008 — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.